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Abstract
 
Patients with human immunodeficiency virus 1–associated immunological thrombocytopenia
(HIV-1–ITP) have markedly elevated platelet-bound immunoglobulin (Ig)G, IgM, and C3C4,
as well as serum circulating immune complexes (CICs) composed of the same. Affinity purifi-
cation of IgGs from their CICs with fixed platelets reveals high-affinity antibody (Ab) against
platelet glycoprotein (GP)IIIa 49–66, which correlates inversely with their platelet count.
However, sera from these patients have little to no anti-GPIIIa activity. To investigate this, we
assayed serum, purified serum IgG, and CIC-Ig from these patients. This revealed 
 
z
 
150-fold
greater Ab activity in purified serum IgG, and 
 
z
 
4,000-fold greater reactivity in CIC-IgG. This
was shown to be associated with the presence of antiidiotype Ab2 (both IgG and IgM) seques-
tered in the CIC-IgG. The IgM antiidiotype was predominantly blocking Ab, as demonstrated
by specificity for F(ab
 
9
 
)
 
2
 
 fragments of anti–GPIIIa 49–66 of HIV-1–ITP patients and inhibition
of reactivity with peptide GPIIIa 49–66, not with a control peptide. The IgM antiidiotype was
not polyreactive. Similar measurements were made in nonthrombocytopenic HIV-1–infected
patients. Their serum reactivity was not measurable, but serum Ig and CIC-IgG against platelet
GPIIIa 49–66 was present, although considerably lower than that found in HIV-1–ITP patients
(26- and 35-fold lower, respectively). In addition, their IgM antiidiotype reactivity was 12-fold
greater than that found in HIV-1–ITP patients. The IgM antiidiotype Ab titer of both cohorts
correlated with in vivo platelet count (
 
r
 
 5 
 
0.7,
 
 P 
 
5 
 
0.0001,
 
 n 
 
5 
 
32). To test the in vivo effec-
tiveness of the IgM antiidiotype, thrombocytopenia was induced in mice with 25 
 
m
 
g of affin-
ity-purified anti–GPIIIa 49–66 (mouse GPIIIa has 83% homology with human GPIIIa and Fc
receptors for human IgG1). Maximum effect was obtained at 4–6 h after intraperitoneal injec-
tion into Balb/c mice with a platelet count of 
 
z
 
30% baseline value. Preincubation of the anti-
GPIIIa Ab with control IgM at molar ratios of IgM/IgG of 1:7 before intraperitoneal injection
had no effect on the in vivo platelet count, whereas preincubation with patient IgM antiidio-
type improved the platelet count to 50–80% of normal. Thrombocytopenia could be reversed
after addition of IgM antiidiotype 4 h after induction of thrombocytopenia. Thus, CICs of
HIV-1–infected patients contain IgM antiidiotype Ab against anti-GPIIIa, which appears to
regulate their serum reactivity in vitro and their level of thrombocytopenia in vivo.
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Introduction
 
Immunological thrombocytopenia is a common complica-
tion of HIV-1 infection. The incidence in HIV-1–infected
patients of HIV-1–associated immunological thrombocy-
topenia (HIV-1-ITP)
 
1
 
 is 0–21% at onset and increases to
30% or more with the development of AIDS (1, 2). Kinetic
data on platelet survival strongly suggest that early-onset
HIV-1–ITP is secondary to increased peripheral destruc-
tion of platelets, whereas patients with AIDS are more
likely to have decreased platelet production (3). Patients
 
Address correspondence to Simon Karpatkin, New York University
Medical Center, 550 First Ave., New York, NY 10016. Phone: 212-263-
5609; Fax: 212-263-0695; E-mail: simon.karpatkin@med.nyu.edu
 
1
 
Abbreviations used in this paper: 
 
ATP, autoimmune thrombocytopenia;
CIC, circulating immune complex; GP, platelet glycoprotein; HIV-1–
ITP, immunological thrombocytopenia associated with HIV-1–infection;
IC, immune complex. 
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with early-onset HIV-1–ITP have a thrombocytopenic
disorder that is clinically indistinguishable from classic au-
toimmune thrombocytopenia (ATP), seen predominantly
in females (4–7). However, HIV-1–ITP is different from
classic ATP with respect to the predominant male inci-
dence and the markedly elevated platelet-associated IgG,
IgM, and C3C4, as well as presence of circulating serum
immune complexes (CICs) composed of the same (5, 6).
These complexes contain anti-F(ab
 
9
 
)
 
2
 
 Abs (8) as well as
HIV-1–related Abs (9, 10). Affinity purification of IgGs
from their CICs with platelets has revealed high-affinity
IgG1 Ab against the platelet integrin glycoprotein (GP)IIIa
peptide 49–66 (11, 12). This serum anti-GPIIIa Ab corre-
lates inversely with platelet count (
 
r
 
 5 
 
0.71; reference 12)
and induces severe thrombocytopenia in mice (12), which
can be prevented and/or reversed with GPIIIa 49–66 pep-
tide (reference 12; mouse GPIIIa is 83% homologous with
human GPIIIa, and macrophages have Fc receptors for hu-
man IgG1).
However, we have recently observed that sera from
HIV-1–ITP patients have considerably less anti–GPIIIa 49–
66 reactivity compared with 
 
z
 
150-fold greater reactivity in
purified IgG from serum and 
 
z
 
4,000-fold greater reactivity
sequestered in their serum CICs. This suggested the possi-
bility of blocking or antiidiotype Ab against anti-GPIIIa in
these patients.
This report documents the presence of blocking IgM
antiidiotype antibody (Ab2
 
b
 
 and/or Ab2
 
g
 
) versus anti–
GPIIIa 49–66 in these patients, which correlates with their
platelet count (
 
r
 
 5 
 
0.7,
 
 P 
 
5 
 
0.001,
 
 n 
 
5 
 
32) and reverses in
vivo induced thrombocytopenia in mice.
 
Materials and Methods
 
Population. 
 
The population consists of 37 early-onset HIV-
1–infected patients without AIDS (19 homosexuals and 18 drug
abusers). 22 were thrombocytopenic, and 15 had normal platelet
counts. Five control sera were obtained from healthy laboratory
personnel. Seven sera were obtained from classic ATP patients.
 
Purified IgG. 
 
IgG was prepared from serum by ion-exchange
chromatography (13).
 
F(ab
 
9
 
)
 
2
 
. 
 
F(ab
 
9
 
)
 
2 
 
fragments were prepared from purified IgG
by pepsin digestion as described (13), and were shown to be free
of Fc fragments by SDS-PAGE as well as ELISA (13).
 
Immune Complexes. 
 
Immune complexes (ICs) were prepared
from serum by polyethylene glycol precipitation (5). Precipitates
were dissolved in one fifth of their serum volume in 0.01 M PBS,
pH 7.4.
 
Isolation of IgG and IgM from ICs. 
 
IgG and IgM were isolated
and purified as described (11). In brief, polyethylene glycol
(PEG)-ICs were applied to a staphylococcal protein A affinity
column (Sigma-Aldrich). The bound complex was washed with
PBS and eluted with 0.1 M glycine buffer, pH 2.5. The eluted
material was applied to an acidified sephadex G-200 gel filtration
column (Amersham Pharmacia Biotech) preequilibrated with the
same elution buffer. Effluents of the IgG peak were isolated, neu-
tralized, dialyzed against PBS, and applied to a rabbit anti-IgM
affinity column (ICN Pharmaceuticals, Inc.) prepared from Affi-
Gel 10 (Bio-Rad). The flow-through material was free of con-
taminating IgM by immunoblot and ELISA. Effluents of the IgM
 
peak were isolated, neutralized, dialyzed against PBS, and applied
to an anti–Fc receptor affinity column to remove rheumatoid fac-
tor. (Fc fragments were prepared by papain digestion [11] and af-
finity purified on a staphylococcal protein A column; the acid
eluate was verified by SDS-PAGE and was coupled to Affi-Gel
10). The flow-through IgM was devoid of rheumatoid factor, as
determined by inability to bind to a second Fc column.
 
Affinity Purification of Antiplatelet IgG. 
 
Antiplatelet IgG was
affinity purified with 10
 
8
 
 platelets fixed with 2% paraformalde-
hyde for 2 h at room temperature, followed by overnight gentle
rocking at 4
 
8
 
C, then acid elution and neutralization, as described
(11). The IgG subclass, determined by radial immunodiffusion
(The Binding Site), was IgG1 with both k and l light chains.
 
Affinity Purification of Antiplatelet GPIIIa 49–66. 
 
Peptide
GPIIIa 49–66, CAPESIEFPVSEARVLED (synthesized by Qual-
ity Controlled Biochemicals), was coupled to an affinity column
with the heterobifunctional cross-linker sulfo-succinimidyl 4-(
 
N
 
-
maleimidomethyl) cyclohexane-1-carboxylate as recommended
by the manufacturer (Pierce Chemical Co.; cross-links the resin
with NH
 
2
 
-terminal cysteine of the peptide), and was incubated
with 0.4 ml of affinity-purified IgG overnight at 4
 
8
 
C. The col-
umn was then washed, eluted at pH 2.5, and neutralized as de-
scribed (12).
 
ELISA. 
 
Antibody reactivity was measured by solid-phase
ELISA (12, 13) using serial doubling dilutions of IgG or IgM on
U-shaped polyvinyl microtitre plates (Curtin-Matheson Scien-
tific) preincubated overnight at 4
 
8
 
C with 200 ng of peptide GPI-
IIa 49–66 or F(ab
 
9
 
)
 
2
 
 fragment of anti–GPIIIa 49–66 in PBS, and
was blocked with 2.5% BSA in PBS. A minimum of two differ-
ent F(ab
 
9
 
)
 
2 
 
fragments were used for each experiment. The first
Ab, used to detect IgG binding, was a 1:500 dilution of goat
F(ab
 
9
 
)
 
2
 
 anti–human IgG (
 
g
 
 chain specific) coupled to alkaline
phosphatase (Sigma-Aldrich). The second Ab, used to detect IgM
binding, was a 1:1,000 dilution of goat F(ab
 
9
 
)
 
2
 
 anti–human IgM
(
 
m
 
 chain specific) coupled to alkaline phosphatase (ICN Pharma-
ceuticals, Inc.). Appropriate enzyme substrate was added, and
color was read in an automated micotitre plate reader at 405 nm.
In some experiments, bound anti–GPIIIa 49–66 was preincu-
bated with GPIIIa 49–66 peptide for 2 h at room temperature
before testing for antiidiotype Ab binding.
 
IgM Ab Titer.
 
IgM Ab titer refers to the reciprocal of the
lowest concentration of IgM Ab (
 
m
 
g/well) capable of binding to
its antigen, determined by extrapolation of the linear portion of
the binding curve to zero binding.
 
Induction of Thrombocytopenia in Mice with Anti–GPIIIa 49–66.
 
Human affinity-purified anti–GPIIIa 49–66 (25 
 
m
 
g) was in-
jected intraperitoneally into BALB/c mice (Taconic Farms), and
blood was drawn from the retroorbital sinus at various times. In
some experiments, anti–GPIIIa 49–66 Ab was preincubated with
either control IgM or antiidiotype IgM before intraperitoneal in-
jection; in other experiments, control or antiidiotype IgM was
given after 4 h of thrombocytopenia. Platelet counts were deter-
mined from 20 
 
m
 
l of blood drawn into Unopettes (no. 5855;
Becton Dickinson) containing optimal anticoagulant concentra-
tion and diluent for quantitating platelet count by phase micros-
copy.
 
Results
 
Fig. 1 demonstrates a comparison of the relative binding
reactivity of serum, serum IgG, and purified IC-IgG for
peptide GPIIIa 49–66 in a representative experiment of 
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five different patients (Table I, HIV-1–ITP). 50% detec-
tion sensitivity for the respective Ab cohorts were 
 
z
 
125,
0.8, and 0.03 
 
m
 
g/well. Thus, serum IgG has 
 
z
 
150-fold
greater reactivity than serum, and IC-IgG has approxi-
mately sevenfold greater reactivity than serum IgG (
 
z
 
4,000-
fold greater than serum). Similar studies performed on sera
of nonthrombocytopenic HIV-1–infected patients also
detected antiplatelet GPIIIa 49–66 in their serum IgG
and CIC-IgG, but at considerably lower levels (25- and
35-fold less, respectively; Table I; HIV-1 controls). This
 
suggested the possibility of blocking or antiidiotype Ab in
serum.
In contradistinction to HIV-1–ITP patients, minimal to
absent serum antiplatelet reactivity was noted in seven clas-
sic ATP patients, with no enhancement of reactivity noted
with serum IgG or IC-IgG (data not shown).
 
Presence of IgG Antiidiotype Ab versus Anti–GPIIIa 49–66.
 
Fig. 2 A demonstrates binding of purified IC-IgG Ab
from five different HIV-1–ITP patients to F(ab
 
9
 
)
 
2
 
 frag-
ments of affinity-purified anti–GPIIIa 49–66. 50% binding
was observed at 
 
z
 
2 
 
m
 
g/ml. Similar results were obtained
with a second F(ab
 
9
 
)
 
2
 
 fragment (data not shown). No bind-
ing was obtained with the same five IC-IgG preparations
against two different control F(ab
 
9
 
)
 
2
 
 fragments (one of
which is shown in Fig. 2). No binding was obtained with
five different control IC-IgG preparations (data not
shown).
Fig. 3 A demonstrates poor to partial blocking of binding
of IgG antiidiotype Ab to anti–GPIIIa 49–66 with peptide
GPIIIa 49–66. Thus, only 20% of Ab binding could be in-
hibited at a peptide/F(ab
 
9
 
)
 
2
 
 molar ratio of 1,024:1, and
therefore designated blocking (
 
P 
 
, 
 
0.05 for last three con-
centrations of peptide; one-tail Student’s 
 
t
 
 test).
 
Presence of IgM Antiidiotype Ab versus Anti–GPIIIa 49–66.
 
Fig. 2 B demonstrates binding of IgM Ab to anti–GPIIIa
49–66. 50% binding was observed at 
 
z
 
1.25 
 
m
 
g/ml.
Similar results were obtained with a second F(ab
 
9
 
)
 
2
 
 frag-
ment (data not shown). IgM antiidiotype specificity was
next examined against five different control F(ab
 
9
 
)
 
2
 
 frag-
ments and four different antigens to determine whether this
IgM could represent polyclonal germline IgM secreted by
Figure 1. Antiplatelet GPIIIa 49–66 reactivity of serum, serum IgG,
and IC-IgG of one representative HIV-1–ITP patient of five patients
studied. Various IgG concentrations of serum, purified serum IgG, and
purified IC-IgG were assayed for anti–GPIIIa 49–66 reactivity by solid-
phase ELISA as described in Materials and Methods.
 
Table I.
 
Clinical and Immunological Data on HIV-1–ITP and HIV-1 Control Patients
 
anti–GPIIIa 49–46 50% Binding
Patient Age Sex Hx PC Serum IgG IC-IgG
Reciprocal titer IgM Ab2
 
b
 
versus anti–GPIIIa 49–66
 
m
 
g/well
 
HIV-1–ITP 2 34 M HS 114 62 0.156 0.025 354
21 40 M HS 87 125 0.156 0.025 690
5 26 M IVDA 52 125 0.156 0.050 930
3 38 M HS 40 125 3.13 0.025 420
20 33 F IVDA 31 62 3.13 0.025 154
log mean: 1.1 0.029 430
HIV-1 controls 49 29 M IVDA 261 NM 32 0.6 2,128
54 35 M HS 257 NM 32 0.6 6,666
47 36 M IVDA 187 NM 16 1.3 8,333
48 43 M IVDA 173 NM 32 1.3 6,666
53 37 M HS 164 NM 32 1.3 4,762
log mean: 28 1.0 5,188
Hx, history; HS, homosexual; IVDA, intravenous drug abuser; PC, platelet count/
 
m
 
l; NM, not measurable. 
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CD5
 
1 
 
B1 cells (14). No binding was obtained with 16 pos-
itively reacting IC-IgM preparations against five different
control F(ab
 
9
 
)
 
2 
 
fragments. One of these experiments is
shown in Fig. 2 B. No binding to anti–GPIIIa 49–66 was
obtained with five different control IgM preparations made
from control subject IC-IgM (Fig. 2 B). No binding was
obtained with four different proteins: ovalbumin, soybean
 
trypsin inhibitor, thyroglobulin, or carbonic anhydrase
(Fig. 4).
Fig. 3 B demonstrates considerable blocking of binding
of IgM antiidiotype Ab to anti–GPIIIa 49–66 with peptide
GPIIIa 49–66. Thus, 50% of Ab binding could be inhibited
at a peptide/F(ab
 
9
 
)
 
2
 
 molar ratio of 
 
z
 
1:6.4, and therefore be
designated blocking antibody (Ab2
 
b
 
 and/or Ab2
 
g
 
). No
blocking was noted with irrelevant peptide CGYGP-
KKKRKVGG at a peptide/F(ab
 
9
 
)
 
2
 
 ratio of 1,024:1. IgM
antiidiotype Ab did not bind to peptide GPIIIa 49–66 (five
experiments, data not shown).
Fig. 3 C demonstrates blocking of binding of anti–GPI-
IIa 49–66 to platelets by IgM antiidiotype, not by control
IgM or IgG antiidiotype. Thus, 50% of Ab binding to
platelets could be inhibited at an IgM/IgG molar ratio of
 
z
 
1:10.
 
Correlation between IgM Antiidiotype Ab versus Anti–GPIIIa
49–66 and Patient’s Platelet Count. 
 
The above data sug-
gested that the reason for the relatively weak serum anti–
GPIIIa 49–66 reactivity with its Ag was because of the
presence of IgM blocking antiidiotype Ab in its serum. We
therefore reasoned that if this were true and pathophysio-
logically relevant, then a positive correlation should be ob-
tained between the antiidiotype titer and the patient’s
platelet count. This proved to be the case. Fig. 5 demon-
strates such a correlation of 
 
r
 
 5 
 
0.71 (
 
P
 
 5 
 
0.001, n 5 32).
Specific measurements and clinical data are described in
Table I, lanes 1–9. In these two cohorts, IgM antiidiotype
Ab was 12-fold greater in nonthrombocytopenic patients.
A similar log mean IgM antiidiotype Ab titer of 1:3,643
was found in 10 additional nonthrombocytopenic HIV-1
patients.
IgM Antiidiotype versus Anti–GPIIIa 49–66 Reverses In
Vivo Thrombocytopenia Induced in Mice by Anti–GPIIIa 49–66.
Our previous study demonstrated that human anti–GPIIIa
49–66 Ab could induce significant thrombocytopenia in
mice, with nadir at 4 h when injected intraperitoneally
(control IgG had no effect; reference 12). We therefore
tested the ability of the IgM antiidiotype Ab versus anti–
GPIIIa 49–66 to reverse this effect in vivo. Again, this
proved to be the case. Thus, Fig. 6 A demonstrates a 70%
drop in platelet count induced by 25 mg/ml of anti–GPIIIa
49–66, with reversal to 50–80% of normal by preincuba-
tion with IgM antiidiotype/anti–GPIIIa 49–66 ratios of
1:7, respectively. Neither control IgM nor IgG-antiidiotype,
at similar ratios, had any effect. To rule out the possibility
that the IgM antiidiotype Ab was not operating through
increased clearance of the antiplatelet Ab, experiments
were also performed after induction of the thrombocytope-
nia at 4 h. Fig. 6 B demonstrates reversal of thrombocy-
topenia with the IgM antiidiotype Ab, not with the IgG
antiidiotype, thus confirming that the IgM antiidiotype was
interfering with the binding of anti-GPIIIa to platelets.
Discussion
These data clearly indicate the presence of IgG and IgM
antiidiotype (Ab2) against anti–GPIIIa 49–66 in HIV-1–
Figure 2. IgG and IgM antiidiotype reactivity against F(ab9)2 fragments
of affinity-purified antiplatelet GPIIIa 49–66. (A) IgG antiidiotype. Puri-
fied IC-IgG was reacted with anti–GPIIIa 49–66 by solid-phase ELISA.
The mean 6 SEM of five IC-IgG experiments (d) is given. Similar re-
sults were obtained with a second anti–GPIIIa 49–66 F(ab9)2 fragment.
The same five IC-IgG samples were nonreactive with four different con-
trol F(ab9)2 fragments, one of which is shown (s). The blank rate with-
out second detecting Ab varied between 0.025–0.100 OD units. (B) IgM
antiidiotype. Purified IC-IgM was reacted with anti–GPIIIa 49–66. The
mean 6 SEM of five experiments (j) is given. Similar results were ob-
tained with a second anti–GPIIIa 49-66 F(ab9)2 fragment. No reactivity
was noted with 16 IC-IgM preparations against five different control
F(ab9)2 preparations, one of which is shown (s). No reactivity was noted
with five control IgM preparations against two patient F(ab9)2 fragments,
one of which is shown (d). The blank rate without second detecting Ab
varied from 0.130–0.145 OD units.2097 Nardi and Karpatkin
ITP patients. Their absence in classic ATP patients suggests
that the mechanism of thrombocytopenia is different in
both autoimmune disorders. The antiidiotype in HIV-1–
ITP patients was both Ab2a as well as blocking (Ab2b
and/or Ab2g) for both isotypes, with blocking IgM Ab2
predominating over IgG Ab2. Several lines of evidence
support the conclusion that blocking IgM Ab2 is responsi-
ble for the impaired serum reactivity of anti–GPIIIa 49–66:
(a) purification of serum IgG and IC-IgG increased anti-
GPIIIa reactivity z150- and 4,000-fold, respectively; (b)
IgM purified from PEG-IC bound to anti–GPIIIa 49–66 in
a specific manner (no binding with control IgM); (c) IgM
Ab could be blocked from binding to anti–GPIIIa 49–66
with the Ag for anti–GPIIIa 49-66 (not with an irrelevant
Ag); (d) anti–GPIIIa 49–66 could be blocked from binding
to platelets with IgM antiidiotype, not with control IgM or
IgG antiidiotype; and (e) in vivo thrombocytopenia in-
duced in mice with anti–GPIIIa 49–66 could be reversed
with purified IC-IgM, not with purified serum IgM or
IC-IgG.
Figure 3. Presence of IgG and IgM antiidiotype reactivity against anti–GPIIIa 49–66. (A) IgG antiidiotype. Various molar ratios of peptide/F(ab9)2
anti–GPIIIa 49–66 fragments were preincubated as described in Materials and Methods before addition of antiidiotype Ab. The mean is given for five ex-
periments. (B) IgM antiidiotype. Various molar ratios of peptide/F(ab9)2 fragments were preincubated before addition of the IgM antiidiotype. The mean
is given for five experiments (j). The mean of five additional experiments with irrelevant peptide is also given (d). (C) Inhibition of anti–GPIIIa 49–66
binding to platelets with IgM antiidiotype. Binding of anti–GPIIIa 49–66 was measured by solid-phase ELISA, using goat F(ab9)2 anti–human IgG cou-
pled to alkaline phosphatase (11). Patient IC-IgM (d) or control IgM (s) or patient IC-IgG (m) was preincubated with affinity-purified anti–GPIIIa 49–
66 at various molar ratios (IgM/IgG or IgG/IgG) for 2 h at room temperature, then was applied to platelets bound to the microtitre plate, blocked, and
washed with 5% BSA-PBS. Symbols in the lower corner of the right vertical line refer to various control measurements: platelets plus IC-IgM plus detec-
tion Ab (n), blocked plates plus anti–GPIIIa 49-66 plus IC-IgM plus detection Ab (1), and platelets plus detection Ab (h). Representative of four dif-
ferent IgM antiidiotype preparations.
Figure 4. Specificity of IgM antiidiotype Ab for anti–GPIIIa 49–66.
Four unrelated antigens, ovalbumin (OVAL), soybean trypsin inhibitor
(SBTI), thyroglobulin (THYR), and carbonic anhydrase (CARB), were
applied to a microtitre plate in addition to the F(ab9)2 fragment of anti–
GPIIIa 49–66 and reacted with the IgM antiidiotype Ab versus anti–
GPIIIa 49–66. OD refers to the highest value obtained in the linear range
of the dilution curve. Blank (BLK) refers to reactivity without the pri-
mary Ab. The mean of five experiments is given.
Figure 5. Correlation between HIV-1–ITP patient’s platelet count in
vivo with IgM antiidiotype titer in vitro. IgM Ab titer refers to the recip-
rocal of the lowest concentration (mg/well) of IgM antiidiotype reactivity
with anti–GPIIIa 49–66, obtained by extrapolation of the linear Ab dilu-
tion curve to the x-axis.2098 Antiidiotype Antibody versus Platelet Anti-GPIIIa in HIV-1–ITP
These data strongly suggest that the IgM antiidiotype as
well as level of anti–GPIIIa 49–66 IgG Ab play a role in
regulating early-onset autoimmune HIV-1–ITP in vivo. A
correlation of platelet count with IgM antiidiotype of r 5
0.7 supports this suggestion, as do our previous observa-
tions on the presence of an inverse correlation between
anti–GPIIIa 49–66 antibody and platelet count in early-
onset HIV-1 infection (thrombocytopenic versus nonthrom-
bocytopenic; reference 12). It should be recognized that
multiple factors are likely to regulate the platelet count in
HIV-1–ITP patients. These include platelet production,
platelet survival, and relative phagocytic function of the
reticuloendothelial system. It is therefore not surprising that
the correlation coefficient is ,1.
The presence of anti–GPIIIa 49–66 Ab in nonthrom-
bocytopenic patients, albeit at 26–35-fold lower reactivity
than in HIV-1–ITP patients, is of interest and suggests that
low levels of reactivity may be present in most early-onset
HIV-1–infected patients. It is possible that this may repre-
sent molecular mimicry between anti–HIV-1 Abs and
platelet GPIIIa. Indeed, this has been reported for anti–
HIV-1–gp120 Ab (15).
Our findings on the presence of blocking IgM antiidio-
type in HIV-1–ITP patients is reminiscent of previous ob-
servations on IgM Abs blocking natural polyreactive low-
affinity Abs in mice as well as humans (16–19). However,
our anti–GPIIIa 49–66 autoantibody preparation is differ-
ent, in that it is highly specific (11) and contains high-affin-
ity Ab (Kd 5 1–2 nM; reference 11). In addition, the puri-
fied serum IgG of HIV-1–ITP patients is 150-fold more
reactive than serum, compared with the 3–5-fold greater
reactivity reported for purified IgG blocking Ab in normal
subjects (18). It is possible that anti–GPIIIa 49–66 was orig-
inally a polyreactive natural Ab that underwent somatic
mutation and selective pressure by antigens (HIV-1), as has
been suggested for the development of autoimmune disease
(17). This is supported by the presence of lower affinity
(Kd 5 7–12 nM) Ab as well in our anti–GPIIIa 49–66
preparation (11). The same selective pressure could also ap-
ply for natural, polyreactive, low-affinity IgM “antiidio-
type” Ab.
Alternatively, the pathogenic potential of low-affinity
IgM Ab has recently been demonstrated in a study compar-
ing monoclonal mouse IgM anti-RBC Ab with its IgG
class-switch variant (20). In these studies, the RBC binding
activity of the IgM Ab was 1,000 times that of its IgG class-
switch variant and was related to its pentameric structure,
which promoted binding, agglutination of RBCs, and
hemolytic anemia. These data indicate that affinity matura-
tion of autoantibodies may not be required for generation
of autoantibodies capable of inducing clinical pathology.
The same applies for the reactivity of the IgM antiidiotype
of our study.
Although the role of antiidiotype Ab in the regulation of
the immune response is controversial, a case can be made
for its dysregulation in the pathophysiology of some au-
toimmune diseases: (a) patients with severe, uncontrolled
SLE have high levels of anti-DNA Abs and low levels of
anti-F(ab9)2 Abs, whereas patients with quiescent disease
have the reverse (21); (b) patients with systemic vasculitis
have antiidiotype Abs against antimyeloperoxidase and an-
tineutrophil cytoplasmic antigen, with rise in antiidiotype
titer as disease activity subsides (22, 23); and (c) a hemo-
philiac patient with a serious anti–factor VIII (antihemo-
philic factor) inhibitor developed antiidiotype Ab against
anti–factor VIII, which coincided with recovery and the
disappearance of the inhibitor (24). A case for antiidiotype
dysregulation is indirectly supported by other observations:
Figure 6. Prevention and reversal of in vivo thrombocytopenia in-
duced by anti–GPIIIa 49–66 induced in mice with IgM antiidiotype Ab
against anti–GPIIIa 49–66. (A) Prevention. Four to seven mice in each
group were treated intraperitoneally with either anti–GPIIIa 49–66 Ab,
Ab plus control IgM (125 mg), Ab plus antiidiotype IgM (125 mg), Ab
plus antiidiotype IgM (875 mg), or Ab plus antiidiotype IgG (875 mg).
Platelet counts were obtained at various time intervals for 24 h. The mean
platelet count 6 SEM for all four groups was similar (1.72 6 0.56 3 106/
ml). Pt, patient. (B) Reversal. 16 mice were treated intraperitoneally with
25 mg of anti–GPIIIa 49–66, and 4 mice were treated intraperitoneally
with saline. At 4 h, after induction of thrombocytopenia, the 16 anti-
body-treated mice were treated (4 mice in each group) with 875 mg of ei-
ther control IgG, patient (Pt) antiidiotype IgG, control IgM, or patient
antiidiotype IgM, and were followed for 24 h. Note reversal of throm-
bocytopenia with IgM antiidiotype at 6, 8, and 12 h compared with con-
trol IgM (P 5 0.0008, 0.0015, and 0.0137, respectively; paired Student’s t
test), not with IgG antiidiotype or control IgG.2099 Nardi and Karpatkin
(a) patients with thyroid autoimmunity have naturally oc-
curring antiidiotype IgM Ab against antimicrosomal Abs
(25); (b) patients with myasthenia gravis have naturally oc-
curring antiidiotype Abs against acetylcholine receptor Ab
(26); and (c) intravenous g-globulin infusions containing
“antiidiotype” Ab are often effective in the treatment of
patients with autoimmune thyroid disease (25), systemic
vasculitis (22, 23), myasthenia gravis (27), and kawasaki
syndrome (28).
Our results contribute to and extend these observations
in a more definitive manner in HIV-1–ITP. Our observa-
tions demonstrate the presence of high-affinity anti–GPIIIa
49–66 Ab (11, 12), specific blocking IgM antiidiotype Ab,
a positive correlation between IgM antiidiotype and plate-
let count, and most importantly, a reversal of in vivo anti-
body-induced thrombocytopenia with its antiidiotype.
These data support the concept that dysregulation of anti-
idiotype Ab can play a role in the development of autoim-
mune disease in HIV-1–ITP.
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